͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
| | | | Many of the barriers women face in the research workplace are not unique to academia. You can get support and a fresh perspective from outside academia and be part of a community of scientists across the UK working to ensure more women in research reach the top of their careers.
Our Women of Influence mentoring scheme is open to Cancer Research UK-funded fellows and postdocs. It pairs exceptional scientists with leading businesswomen to provide early career researchers with support from outside academia at a critical time in their development.
By partnering with some of the UK’s leading businesswomen, the scheme provides researchers with additional insight into the experience and wisdom of those at the top of their respective fields who are facing similar challenges and decisions.
|
| | |
| | |
|
|
|
|
Funding & Research Opportunities |
| Get in touch with our office for confidential advice on eligibility, remit and funding options prior to applying. |
|
| | | | | | | | | | | | | | | | | | | | Applications accepted year round |
|
|---|
| | | | | | Applications accepted all year round |
|
|---|
| | | | | | Applications accepted all year round |
|
|---|
|
| | |
|
|
| | | | | | | There are only a few days left until the C-Further team shares how they can support your translational paediatric oncology projects.
Learn which projects are eligible, what a well-validated target looks like, about the application process and how to submit a strong expression of interest.
With the second application deadline approaching on 2 March, this is your chance to gain valuable insights and have your questions answered directly by the team. | | |
| | | | | | | Access to high-quality cancer data is crucial for enabling the continued growth of data science and AI in cancer. However, this access has been a barrier to progress, not due to a lack of high-quality data but rather because of challenges in making sure data is findable and accessible.
We hosted a webinar with Joe Day from Cancer Research Horizons discussing the impact that reusing research data can have. Joe outlined some of the key practical considerations needed to make your research data FAIR (findable, accessible, interoperable, reusable) and introduced some of the funding and support available to maximise the impact of your research data.
Didn’t make it? You can watch it back now. | | |
|
|---|
|
|
|
|
Maximising learnings from clinical trials for children’s and young people’s cancers |
| Join us on 12 February as we explore how to maximise learnings from clinical trials to improve outcomes for young patients. |
| | | | | We’ll be joined online by Steve Clifford, Director of the Newcastle University Centre for Cancer, who has a major interest in understanding the biological basis of embryonal brain tumour development and translating these findings to improve clinical treatments. |
|
|---|
| | | | | We’ll also hear from John Rainsbury, chair of the charity Little Hero that funds research into childhood brain tumours and supports families with children undergoing treatment.
Stay tuned for more speaker announcements and updates on social media with #ExploringCYPCancers. |
|
|---|
|
| | |
|
|
New data partnership with Lifebit |
| Our innovation arm, Cancer Research Horizons, has joined Lifebit’s federated data network to expand access to Cancer Research UK-funded datasets.
Cancer Research Horizons will initially make its multi-omic clinically linked colorectal cancer database, S: CORT, available through the platform, with the intention to expand this to other high-quality cancer datasets in the future.
The Lifebit platform will enable these datasets to be combined with those from other leading institutions, facilitating large-scale, population-level analyses. |
| | |
|
|
|
NICE recommends sodium thiosulfate to prevent chemotherapy-induced hearing loss in children and teenagers |
| The National Institute for Health and Care Excellence has issued a new recommendation supporting the use of sodium thiosulfate to prevent hearing loss in children and adolescents, aged 0–17, undergoing cisplatin chemotherapy for localised solid tumours.
This guidance is based on results from our SIOPEL-6 clinical trial which demonstrated that administering sodium thiosulfate following cisplatin chemotherapy significantly reduced the incidence of ototoxicity in children and young people with hepatoblastoma, without compromising the efficacy of the chemotherapy. |
| | |
|
|
|
Help us maximise the impact of your research by telling us about your publications |
| Do you receive funding from us? We need to hear about your publications so that we can maximise its impact, whether by disseminating findings across the research community, communicating new discoveries to patients and the public or showing donors and supporters the impactful research they help fund.
The process is simple and confidential. Take part in improving the impact of important cancer research discoveries. |
| | |
|
|
|
| | Together we are
beating cancer |
| | |
|---|
|
|
|
| | | You are playing a crucial role in helping us beat cancer, so we'd like to continue to keep you updated on what we're up to. You can manage your preferences and unsubscribe here.
Your details are safe with us. Check out our Privacy Policy.
Our supporters are at the heart of everything we achieve at Cancer Research UK. Read our Fundraising Promise.
This email is from Cancer Research UK. Cancer Research UK is a registered charity in England and Wales (1089464), Scotland (SC041666), the Isle of Man (1103) and Jersey (247). A company limited by guarantee. Registered company in England and Wales (4325234) and the Isle of Man (5713F). Registered address: 2 Redman Place, London, E20 1JQ. |
|
|
|
